TELADOC HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.01 USD | -2.40% |
|
+0.23% | -39.63% |
| Apr. 26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
| Apr. 26 | Oppenheimer Cuts Teladoc's Price Target to $21 From $26, Maintains Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,060 | 28,986 | 14,699 | 3,830 | 3,568 | 2,203 | - | - |
| Enterprise Value (EV) 1 | 5,986 | 29,622 | 15,051 | 4,466 | 4,026 | 2,553 | 2,278 | 1,996 |
| P/E ratio | -60.7 x | -37.3 x | -33.6 x | -0.28 x | -16.1 x | -12.4 x | -19.9 x | -25.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 11 x | 26.5 x | 7.23 x | 1.59 x | 1.37 x | 0.83 x | 0.8 x | 0.77 x |
| EV / Revenue | 10.8 x | 27.1 x | 7.4 x | 1.86 x | 1.55 x | 0.96 x | 0.83 x | 0.7 x |
| EV / EBITDA | 188 x | 234 x | 56.2 x | 18.1 x | 12.3 x | 6.99 x | 5.46 x | 4.45 x |
| EV / FCF | 316 x | -372 x | 79.2 x | 25.8 x | 30.9 x | 11.9 x | 8.23 x | 6.36 x |
| FCF Yield | 0.32% | -0.27% | 1.26% | 3.87% | 3.23% | 8.41% | 12.2% | 15.7% |
| Price to Book | 6.01 x | 1.14 x | 0.9 x | 1.65 x | 1.52 x | 0.96 x | 0.96 x | 0.96 x |
| Nbr of stocks (in thousands) | 72,382 | 144,961 | 160,087 | 161,927 | 165,557 | 169,314 | - | - |
| Reference price 2 | 83.72 | 200.0 | 91.82 | 23.65 | 21.55 | 13.01 | 13.01 | 13.01 |
| Announcement Date | 2/26/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 553.3 | 1,094 | 2,033 | 2,407 | 2,602 | 2,665 | 2,760 | 2,862 |
| EBITDA 1 | 31.83 | 126.8 | 267.8 | 246.5 | 328.1 | 365.5 | 417 | 448.2 |
| EBIT 1 | -80.44 | -506.4 | -265.6 | -13,653 | -248.6 | -224 | -127.3 | -7.436 |
| Operating Margin | -14.54% | -46.29% | -13.07% | -567.27% | -9.55% | -8.41% | -4.61% | -0.26% |
| Earnings before Tax (EBT) 1 | -109.5 | -576 | -384.7 | -13,663 | -219.6 | -178.6 | -114.4 | -28.79 |
| Net income 1 | -98.86 | -485.1 | -428.8 | -13,660 | -220.4 | -170.9 | -110.2 | -68.59 |
| Net margin | -17.87% | -44.35% | -21.09% | -567.53% | -8.47% | -6.41% | -3.99% | -2.4% |
| EPS 2 | -1.380 | -5.360 | -2.730 | -84.60 | -1.340 | -1.053 | -0.6535 | -0.5086 |
| Free Cash Flow 1 | 18.97 | -79.55 | 189.9 | 172.8 | 130.1 | 214.8 | 276.9 | 313.9 |
| FCF margin | 3.43% | -7.27% | 9.34% | 7.18% | 5% | 8.06% | 10.03% | 10.97% |
| FCF Conversion (EBITDA) | 59.59% | - | 70.92% | 70.1% | 39.64% | 58.76% | 66.41% | 70.04% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 521.7 | 554.2 | 565.4 | 592.4 | 611.4 | 637.7 | 629.2 | 652.4 | 660.2 | 660.5 | 646.1 | 657.4 | 675.6 | 688.8 | 673.3 |
| EBITDA 1 | 67.37 | 77.08 | 54.5 | 46.71 | 51.21 | 94.09 | 52.76 | 72.16 | 88.76 | 114.4 | 63.14 | 79.08 | 97.48 | 129.3 | 80.76 |
| EBIT 1 | -60.58 | -41.43 | -6,669 | -3,097 | -71.73 | -3,816 | -77.1 | -71.64 | -64.72 | -35.08 | -87.12 | -70.31 | -42.75 | -23.83 | -60.8 |
| Operating Margin | -11.61% | -7.47% | -1,179.69% | -522.73% | -11.73% | -598.32% | -12.25% | -10.98% | -9.8% | -5.31% | -13.48% | -10.7% | -6.33% | -3.46% | -9.03% |
| Earnings before Tax (EBT) 1 | -80.7 | -60.73 | -6,674 | -3,103 | -74.65 | -3,812 | -68.55 | -66.13 | -59.56 | -25.38 | -79.2 | -59.65 | -37.75 | -2.951 | -53.73 |
| Net income 1 | -84.34 | -10.98 | -6,675 | -3,101 | -73.48 | -3,810 | -69.23 | -65.18 | -57.07 | -28.89 | -81.89 | -53.79 | -33.75 | -0.2634 | -55.79 |
| Net margin | -16.17% | -1.98% | -1,180.6% | -523.56% | -12.02% | -597.46% | -11% | -9.99% | -8.64% | -4.37% | -12.67% | -8.18% | -4.99% | -0.04% | -8.29% |
| EPS 2 | -0.5300 | -0.0700 | -41.58 | -19.22 | -0.4500 | -23.49 | -0.4200 | -0.4000 | -0.3500 | -0.1700 | -0.4900 | -0.3258 | -0.2204 | -0.0306 | -0.2928 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/27/21 | 2/22/22 | 4/27/22 | 7/27/22 | 10/26/22 | 2/22/23 | 4/26/23 | 7/25/23 | 10/24/23 | 2/20/24 | 4/25/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 636 | 352 | 637 | 458 | 351 | 75.3 | - |
| Net Cash position 1 | 73.9 | - | - | - | - | - | - | 206 |
| Leverage (Debt/EBITDA) | - | 5.011 x | 1.315 x | 2.582 x | 1.395 x | 0.959 x | 0.1806 x | - |
| Free Cash Flow 1 | 19 | -79.6 | 190 | 173 | 130 | 215 | 277 | 314 |
| ROE (net income / shareholders' equity) | -9.75% | -5.74% | -2.69% | -149% | -9.51% | -4.73% | -4.54% | -4.7% |
| ROA (Net income/ Total Assets) | -6.31% | -5.01% | -2.42% | -2.15% | -5.04% | -3.33% | -3.05% | -2.15% |
| Assets 1 | 1,566 | 9,679 | 17,745 | 635,150 | 4,369 | 5,137 | 3,613 | 3,187 |
| Book Value Per Share 2 | 13.90 | 175.0 | 102.0 | 14.30 | 14.10 | 13.60 | 13.60 | 13.60 |
| Cash Flow per Share 2 | 0.4200 | -0.5900 | 1.240 | 1.210 | 2.130 | 2.070 | 2.340 | 2.680 |
| Capex 1 | 10.9 | 26 | 63.9 | 173 | 156 | 141 | 147 | 153 |
| Capex / Sales | 1.97% | 2.38% | 3.15% | 7.18% | 6.01% | 5.3% | 5.33% | 5.36% |
| Announcement Date | 2/26/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
13.01
USD
Average target price
18.2
USD
Spread / Average Target
+39.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.63% | 2.2B | |
| +40.45% | 2.68B | |
| +22.83% | 527M | |
| +42.77% | 467M | |
| -64.56% | 156M | |
| -31.65% | 85.12M |
- Stock Market
- Equities
- TDOC Stock
- Financials Teladoc Health, Inc.
